Literature DB >> 6333416

HLA-A,B,C and DR antigen frequencies in acquired immunodeficiency syndrome (AIDS) patients with opportunistic infections.

M S Pollack, J Gold, C E Metroka, B Safai, B Dupont.   

Abstract

During the past three years, an epidemic of acquired immunodeficiency syndromes (AIDS) involving the presence of specific forms of cancer (notably Kaposi's sarcoma) and infection (e.g., pneumocystis carinii) ordinarily seen only in severely immunosuppressed hosts has occurred among active homosexuals, Haitian immigrants, drug users, and hemophiliacs in large cities in the United States and elsewhere. An as yet unidentified viral agent is presumably the cause of the initial immunodeficiency and host genetic factors may influence the subsequent development of different clinical symptoms in different patients. We have previously reported that the HLA antigens DR5 and DR2 are associated with susceptibility to Kaposi's sarcoma (KS) in different Caucasian subpopulations. We now have also noted that AIDS patients with opportunistic infections have a normal frequency of DR2 and DR5 and a significantly increased frequency of DR3 and that the ultimate clinical expression of AIDS in patients with unexplained lymphadenopathy may depend upon genetic factors associated with these particular DR types.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333416     DOI: 10.1016/0198-8859(84)90048-x

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  Prolonged clinically asymptomatic evolution after HIV-1 infection is marked by the absence of complement C4 null alleles at the MHC.

Authors:  F Hentges; A Hoffmann; F Oliveira de Araujo; R Hemmer
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Defects in antigen presentation of mutant influenza haemagglutinins are reversed by mutations in the MHC class II molecule.

Authors:  A P Warren; I Paschedag; C Benoist; J Peccoud; D Mathis; D B Thomas
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.